Verboom, Diana M. MD, PhD1,2; van de Groep, Kirsten MD, PhD1,2; Boel, C. H. Edwin MD, PhD3; Haas, Pieter Jan A. MD, PhD3; Derde, Lennie P. G. MD, PhD2; Cremer, Olaf L. MD, PhD2; Bonten, Marc J. M. MD, PhD1,3
Author Information
1 Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, the Netherlands.
2 Department of Intensive Care Medicine, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
3 Department of Medical Microbiology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal’s website (http://journals.lww.com/ccmjournal).
Dr. Verboom’s and Bonten’s institutions received funding from the Innovative Medicine Initiative, European Union’s Seventh Framework Programme (FP7/2007–2013), and European Federation of Pharmaceutical Industries and Associations companies’ in-kind contribution (Combatting Bacterial resistance in Europe-Carbapenem-Resistance, grant agreement 115 620). The remaining authors have disclosed that they do not have any potential conflicts of interest.
For information regarding this article, E-mail: [email protected]
doi: 10.1097/CCM.0000000000004717